Analyst Price Targets — LXEO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 13, 2026 11:15 am | Mitchell Kapoor | H.C. Wainwright | $10.00 | $8.12 | TheFly | Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright |
| December 17, 2025 9:09 pm | — | Raymond James | $25.00 | $9.11 | TheFly | Lexeo Therapeutics initiated with a Strong Buy at Raymond James |
| December 10, 2025 11:38 am | Leland Gershell | Oppenheimer | $20.00 | $9.51 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Lexeo Therapeutics (LXEO) |
| November 20, 2025 1:28 pm | — | Cantor Fitzgerald | $19.00 | $9.09 | TheFly | Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald |
| October 21, 2025 10:24 am | — | H.C. Wainwright | $13.00 | $9.22 | TheFly | Lexeo Therapeutics price target lowered to $13 from $15 at H.C. Wainwright |
| October 15, 2025 10:24 am | — | Guggenheim | $30.00 | $8.50 | TheFly | Lexeo Therapeutics initiated with a Buy at Guggenheim |
| October 7, 2025 4:18 pm | — | Chardan Capital | $17.00 | $8.25 | TheFly | Lexeo Therapeutics price target raised to $17 from $15 at Chardan |
| October 7, 2025 3:08 pm | — | H.C. Wainwright | $15.00 | $8.25 | TheFly | Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright |
| October 7, 2025 2:05 pm | Mani Foroohar | Leerink Partners | $20.00 | $8.25 | TheFly | Lexeo Therapeutics price target raised to $20 from $9 at Leerink |
| June 12, 2024 4:12 pm | Brian Skorney | Robert W. Baird | $28.00 | $18.19 | TheFly | Lexeo Therapeutics initiated with an Outperform at Baird |
Latest News for LXEO
SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026 First CMC Development and Readiness Program (CDRP) meeting for LX2006 in Q1 2026; aligned with FDA on flexible approach to process validation such as reduced PPQ manufacturing batches Late-breaking oral presentations at the American College of Cardiology (ACC)…
Shares of Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has assigned a strong buy
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL.
Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) CEO Richard Nolan Townsend sold 10,173 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $6.38, for a total transaction of $64,903.74. Following the completion of the sale, the chief executive officer directly owned 392,483
Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LXEO.
U.S. House Trading
No House trades found for LXEO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.